Abstract 1479P
Background
Refractory cancer pain (RCP) affects 10-20% of cancer patients, exhibiting limited response to standard opioids (OPI). Ketamine (KET), an anesthetic medication, has gained recent attention for its potential in managing RCP. This study aims to describe the consumption of rescue OPI before and after initiating KET, the rate of patients meeting a controlled pain criteria, and its safety profile.
Methods
A prospective observational study was conducted in three academic hospitals. Over an 18-month period, we included all cancer patients who initiated KET therapy based on the criteria of their treating medical team. The frequency of OPI rescues was recorded on days five (D-5) and two (D-2), and on days two (D+2) and five (D+5) pre and post KET initiation, respectively. Controlled pain criteria were defined as a 72-hour interval with no more than 3 OPI rescues per day, absence of breakthrough pain, and no escalation in OPI dosage. All adverse effects (AEs) were recorded in accordance with the CTCAE 5.0 guidelines.
Results
Fifty-two patients were included, and their characteristics are described in the table. The most common initiation dose of KET was 0.5 mg/kg/day orally (71.2%). Median oral morphine milligram equivalent (MME) at initiation of KET was 120mg. Overall survival from the onset of KET therapy was 43 days. Median daily OPI rescue was 3.90 on D-5 and 4.62 on D-2, decreasing to 2.79 on D+2 and 2.77 on D+5 (p=
Conclusions
A significant decrease in rescue opioids usage was observed after initiating ketamine. Over 60% of the patients met the criteria for controlled pain, with a favorable safety profile. Further comparative studies are required to better understand the role of ketamine in cancer pain.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d'Hebron University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10